AMG133 peptidelading (TFA)

AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload. AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of Maridebart cafraglutide (AMG133) (HY-164535) as a peptide linker conjugate[1].

12352209

GCGR

GPCR/G Protein

Metabolism-protein/nucleotide metabolism

Metabolic Disease

99.70

O=C(NC(C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(NCC(NCC(NCC(NCC(NCC(NCC(NCC(N[C@@H](CO)C(NCC(NCC(NCC(NCC(N[C@@H](CO)C(NCC(NCC(NCC(NCC(N[C@@H](CO)C(N[C@@H](CCCCNC(CBr)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)(C)C)[C@H](CC7=CNC=N7)N.OC(C(F)(F)F)=O.[x]

C196H290BrN55O69.xC2HF3O2

4600.70 (free base)

[1]Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6 (2) :290-303.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10736A/AMG133-peptide-payload-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported